About Madrigal
Madrigal is a company based in Lexington (United States) founded in 2000. It operates as a HealthTech. Madrigal has raised $90 million across 3 funding rounds from investors including Caxton Associates, Galleon Group and Military Health. The company has 37 employees as of December 31, 2022. Madrigal has completed 1 acquisition, including Madrigal Pharmaceuticals. Madrigal offers products and services including MASH Treatment. Madrigal operates in a competitive market with competitors including Adicet Bio, Orca Bio, Ossium Health, Auron Therapeutics and Nordic Nanovector, among others.
- Headquarter Lexington, United States
- Employees 37 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Madrigal Pharmaceuticals, Inc.
-
Annual Revenue
$180.13 M (USD)0as on Dec 31, 2024
-
Net Profit
-$465.89 M (USD)-25as on Dec 31, 2024
-
EBITDA
-$497.88 M (USD)-31as on Dec 31, 2024
-
Total Equity Funding
$90 M (USD)
in 3 rounds
-
Latest Funding Round
$999.7 K (USD), Grant
Apr 01, 2011
-
Investors
Caxton Associates
& 2 more
-
Employee Count
37
as on Dec 31, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Madrigal
Madrigal offers a comprehensive portfolio of products and services, including MASH Treatment.
A treatment for metabolic dysfunction-associated steatohepatitis is provided.
People of Madrigal
Unlock access to complete
Area Team
78 people
Leadership Team
68 people
Sales and Marketing
26 people
Operations Team
20 people
Thought Team
13 people
Data Analysis and Operations Team
12 people
Software Development Team
12 people
Product Management Team
11 people
Unlock access to complete
Funding Insights of Madrigal
Madrigal has successfully raised a total of $90M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $999.7 thousand completed in April 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Madrigal
Madrigal has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Caxton Associates, Galleon Group and Military Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified asset management is provided by Caxton Associates.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Administers health care and support for military personnel and operations.
|
Locked | Locked | Locked |
Investor details for Madrigal
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Madrigal
Madrigal has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Madrigal Pharmaceuticals.
Investment portfolio details for Madrigal
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Develops small molecule drugs for the treatment of cardiovascular and metabolic diseases and non-alcoholic steatohepatitis
|
Locked | Locked | 2011 | Locked |
Complete acquisition details for Madrigal
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Madrigal
Detailed financials for Madrigal
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Madrigal Comparisons
Peer comparison for Madrigal
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Madrigal
Madrigal operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adicet Bio, Orca Bio, Ossium Health, Auron Therapeutics and Nordic Nanovector, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Immune cell therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders
|
|
| Locked | Locked | Locked |
Ossium Health is focused on bioengineering for improved health.
|
|
| Locked | Locked | Locked |
Developer of cancer therapeutics for the treatment of blood cancer
|
|
| Locked | Locked | Locked |
Antibody radionuclide conjugates are developed for haematological cancers.
|
|
| Locked | Locked | Locked |
Monoclonal antibody therapies for pediatric leukemia are developed.
|
Detailed competitors of Madrigal
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Madrigal
Complete news archive for Madrigal
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Madrigal
Madrigal was founded in 2000 and raised its 1st funding round 4 years after it was founded.
Madrigal is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Madrigal is a funded company, having raised a total of $90M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Madrigal is 37.
Annual revenue of Madrigal is $180.13M as on Dec 31, 2024.
Madrigal Pharmaceuticals, Inc. is engaged in developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a severe liver condition. The companys efforts are directed towards halting or reversing liver scarring and resolving MASH to prevent complications like cirrhosis. Operating within the biopharmaceutical sector, Madrigal has achieved a significant milestone with the first FDA-approved treatment for MASH. Their solutions target high unmet medical needs in liver disease management across the United States and Europe.
Madrigal's top competitors include Orca Bio, Ossium Health and Adicet Bio.
Madrigal offers MASH Treatment.
Madrigal has made 1 acquisition, including Madrigal Pharmaceuticals.
Madrigal has 3 investors. Key investors include Caxton Associates, Galleon Group, and Military Health.